Compare Abeona Therapeutics Inc (ABEO) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Raymond James Financial, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Raymond James Financial, Inc. trades at $180.17 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is far larger — about 82.2× Abeona Therapeutics Inc's market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | RJF | |
|---|---|---|
Market Cap | $421.19M | $34.63B |
Sector | Health | Financials |
52-Week High | $7.45 | $180.55 |
52-Week Low | $4.17 | $140.89 |
Enterprise Value | $276.10M | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Raymond James Financial (RJF) trades at $179.09, up 1.43% today, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows consistent revenue growth, reaching $13.84B in 2025, and a solid net income margin of 15.37%. Recent news highlights record Q3 2026 revenues and strategic acquisitions as key growth drivers.
The outlook is positive with a consensus price target of $183.75, though risks include market volatility and execution of growth initiatives. The stock presents an opportunity based on fundamental strength and analyst support, balanced by the need to monitor expense management and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
